Published in Methods on September 01, 2006
Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol (2008) 4.60
Virus entry by macropinocytosis. Nat Cell Biol (2009) 3.87
Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci (2009) 2.36
Role of particle size in phagocytosis of polymeric microspheres. Pharm Res (2008) 2.23
Shape induced inhibition of phagocytosis of polymer particles. Pharm Res (2008) 1.91
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.40
Factoring-in agglomeration of carbon nanotubes and nanofibers for better prediction of their toxicity versus asbestos. Part Fibre Toxicol (2012) 1.21
Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des (2009) 1.18
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09
Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity. Proc Natl Acad Sci U S A (2013) 1.01
Biomimetic nanoparticles: preparation, characterization and biomedical applications. Int J Nanomedicine (2010) 1.01
Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat Rev Microbiol (2010) 0.99
In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm (2010) 0.99
Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines (2010) 0.96
Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells. J Immunol Methods (2010) 0.89
Macrophage scavenger receptor A mediates the uptake of gold colloids by macrophages in vitro. Nanomedicine (Lond) (2011) 0.89
Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front Chem (2014) 0.89
Aluminum hydroxide nanoparticles show a stronger vaccine adjuvant activity than traditional aluminum hydroxide microparticles. J Control Release (2013) 0.88
Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum Vaccin Immunother (2013) 0.88
Strategies to guide the antibody affinity maturation process. Curr Opin Virol (2015) 0.87
Calcium condensed LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells. Mol Pharm (2011) 0.86
Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine (2011) 0.85
Dendritic Cell-Mediated Phagocytosis but Not Immune Activation Is Enhanced by Plasmin. PLoS One (2015) 0.85
Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. Mol Pharm (2015) 0.85
Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo. Elife (2015) 0.85
A Candida albicans mannoprotein deprived of its mannan moiety is efficiently taken up and processed by human dendritic cells and induces T-cell activation without stimulating proinflammatory cytokine production. Infect Immun (2008) 0.84
PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity. Hum Vaccin Immunother (2016) 0.82
Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol (2008) 0.81
Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine. Syst Synth Biol (2010) 0.81
TLR 9 activation in dendritic cells enhances salmonella killing and antigen presentation via involvement of the reactive oxygen species. PLoS One (2010) 0.81
LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A. Cell Microbiol (2013) 0.81
Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. PLoS One (2015) 0.80
Single-dose microparticle delivery of a malaria transmission-blocking vaccine elicits a long-lasting functional antibody response. Curr Mol Med (2013) 0.80
Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis. Mol Pharm (2013) 0.80
The Use of Synthetic Carriers in Malaria Vaccine Design. Vaccines (Basel) (2015) 0.80
Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines (2014) 0.79
The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen. Immunology (2012) 0.79
DNA-encapsulated magnesium phosphate nanoparticles elicit both humoral and cellular immune responses in mice. Results Immunol (2014) 0.78
Structure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis. AAPS J (2014) 0.78
A polymer/oil based nanovaccine as a single-dose immunization approach. PLoS One (2013) 0.77
Ultrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation. Int J Nanomedicine (2011) 0.77
Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. PLoS One (2014) 0.77
Polymeric Materials for Gene Delivery and DNA Vaccination. Adv Mater (2008) 0.76
Nanocarrier-based immunotherapy in cancer management and research. Immunotargets Ther (2014) 0.76
Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting. Vaccines (Basel) (2016) 0.76
Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother (2016) 0.76
Insight into the role of N,N-dimethylaminoethyl methacrylate (DMAEMA) conjugation onto poly(ethylenimine): cell viability and gene transfection studies. J Mater Sci Mater Med (2012) 0.76
Effects of ovalbumin protein nanoparticle vaccine size and coating on dendritic cell processing. Biomater Sci (2016) 0.76
Neisseria lactamica antigens complexed with a novel cationic adjuvant. Hum Vaccin Immunother (2013) 0.75
Rehmannia glutinosa polysaccharide liposome as a novel strategy for stimulating an efficient immune response and their effects on dendritic cells. Int J Nanomedicine (2016) 0.75
Fabrication of nanoadjuvant with poly-ε-caprolactone (PCL) for developing a single-shot vaccine providing prolonged immunity. Int J Nanomedicine (2014) 0.75
Effect of Biophysical Properties of Phosphatidylserine Particle on Immune Tolerance Induction Toward Factor VIII in a Hemophilia A Mouse Model. J Pharm Sci (2016) 0.75
Non-invasive administration of biodegradable nano-carrier vaccines. Am J Transl Res (2017) 0.75
Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles. J Immunol Res (2016) 0.75
From Stock Bottle to Vaccine: Elucidating the Particle Size Distributions of Aluminum Adjuvants Using Dynamic Light Scattering. Front Chem (2017) 0.75
Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity. Sci Rep (2017) 0.75
A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms. Sci Rep (2015) 0.75
Synthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial Virus. Vaccines (Basel) (2016) 0.75
Type VI secretion system sheaths as nanoparticles for antigen display. Proc Natl Acad Sci U S A (2016) 0.75
Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci (2017) 0.75
Polyethylenimine-based micro/nanoparticles as vaccine adjuvants. Int J Nanomedicine (2017) 0.75
Nanodiamond enhances immune responses in mice against recombinant HA/H7N9 protein. J Nanobiotechnology (2017) 0.75
Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model. Front Microbiol (2017) 0.75
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med (2004) 2.93
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine (2002) 1.97
IMGT/HighV QUEST paradigm for T cell receptor IMGT clonotype diversity and next generation repertoire immunoprofiling. Nat Commun (2013) 1.71
Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One (2012) 1.64
Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg (2012) 1.62
Natural regulatory T cells and persistent viral infection. J Virol (2007) 1.62
Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol (2004) 1.57
Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A (2013) 1.57
Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog (2011) 1.51
Parasite-dependent expansion of TNF receptor II-positive regulatory T cells with enhanced suppressive activity in adults with severe malaria. PLoS Pathog (2009) 1.46
Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films. Malar J (2008) 1.35
Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus. Mol Pharm (2007) 1.34
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res (2006) 1.33
Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses. J Infect Dis (2008) 1.28
A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use. J Immunol (2009) 1.28
Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS One (2008) 1.25
Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger". Eur J Immunol (2005) 1.23
Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. Am J Trop Med Hyg (2003) 1.22
A regulatory role for CD37 in T cell proliferation. J Immunol (2004) 1.20
Poly-L-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine (2006) 1.16
Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol (2006) 1.16
Plasmodium falciparum-mediated induction of human CD25Foxp3 CD4 T cells is independent of direct TCR stimulation and requires IL-2, IL-10 and TGFbeta. PLoS Pathog (2009) 1.14
Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol (2009) 1.12
Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods (2006) 1.11
Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol (2008) 1.10
Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol (2004) 1.09
Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol (2012) 1.09
Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice. Arthritis Rheum (2005) 1.08
Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog (2009) 1.08
A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci U S A (2003) 1.07
Defining target antigens for CD25+ FOXP3 + IFN-gamma- regulatory T cells in chronic hepatitis C virus infection. Immunol Cell Biol (2007) 1.06
Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol (2009) 1.05
NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections. J Infect Dis (2012) 1.04
Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care (2014) 1.04
Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology (2006) 1.03
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. Breast Cancer Res (2006) 1.03
Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun (2004) 1.02
Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun (2002) 1.02
Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. Angew Chem Int Ed Engl (2011) 1.02
Round and round we go: cyclic peptides in disease. Curr Med Chem (2006) 1.01
Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg (2006) 1.00
Hot, sweet and sticky: the glycobiology of Plasmodium falciparum. Trends Parasitol (2008) 0.99
The effector T cell response to ryegrass pollen is counterregulated by simultaneous induction of regulatory T cells. J Immunol (2010) 0.98
Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines (2008) 0.98
Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol (2002) 0.96
Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J (2014) 0.95
The activin A antagonist follistatin inhibits asthmatic airway remodelling. Thorax (2012) 0.94
Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J Mol Biol (2002) 0.94
Apoptosis and dysfunction of blood dendritic cells in patients with falciparum and vivax malaria. J Exp Med (2013) 0.94
The role of FcgammaRIIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus. Immunol Cell Biol (2003) 0.93
Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J Immunol (2010) 0.93
Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses. Immunol Cell Biol (2005) 0.93
Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta (2009) 0.92
Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. Infect Immun (2013) 0.92
Growth-inhibitory antibodies are not necessary for protective immunity to malaria infection. Infect Immun (2009) 0.91
The adjuvanticity of a mannosylated antigen reveals TLR4 functionality essential for subset specialization and functional maturation of mouse dendritic cells. J Immunol (2008) 0.91
Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J Clin Invest (2002) 0.91
Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines (2008) 0.90
The challenge of assessing infant vaccine responses in resource-poor settings. Expert Rev Vaccines (2010) 0.90
Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J Med Chem (2005) 0.90
Antagonistic effects of human cyclic MBP(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human T-cell proliferation. J Med Chem (2002) 0.90
Dendritic cells: activation and maturation--applications for cancer immunotherapy. Curr Med Chem (2005) 0.89
Methods to measure T-cell responses. Expert Rev Vaccines (2010) 0.89
Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells. J Immunol (2003) 0.89
Low-level Plasmodium falciparum blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers. J Infect Dis (2012) 0.89
Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers. Methods (2013) 0.89
Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy (2013) 0.88
Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming. Eur J Immunol (2006) 0.88
Systemic immune responses in sheep, induced by a novel nano-bead adjuvant. Vaccine (2005) 0.88
Structure and function of the myelin proteins: current status and perspectives in relation to multiple sclerosis. Curr Med Chem (2005) 0.88
Inhibition of destructive autoimmune arthritis in FcgammaRIIa transgenic mice by small chemical entities. Immunol Cell Biol (2008) 0.88
Insights into peptide-based vaccine design for cancer immunotherapy. Curr Med Chem (2005) 0.87
A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J Immunol (2010) 0.86
A double mutation of MBP(83-99) peptide induces IL-4 responses and antagonizes IFN-gamma responses. J Neuroimmunol (2008) 0.86
Selectively impaired CD8+ but not CD4+ T cell cycle arrest during priming as a consequence of dendritic cell interaction with plasmodium-infected red cells. J Immunol (2005) 0.86
The signalling imprints of nanoparticle uptake by bone marrow derived dendritic cells. Methods (2013) 0.86
Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[A91,A96]MBP87-99) induces altered responses in mice after conjugation to mannan: implications in the immunotherapy of multiple sclerosis. J Med Chem (2009) 0.85
Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines (2008) 0.85
Transgenic mice expressing human FcgammaRIIa have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunol Lett (2010) 0.85
The good, the bad and the ugly: how altered peptide ligands modulate immunity. Expert Opin Biol Ther (2008) 0.85
Delivery of a heterologous antigen by a registered Salmonella vaccine (STM1). FEMS Microbiol Lett (2003) 0.84